Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
120.6 CHF | -0.17% | -2.87% | -3.03% |
Mar. 13 | Medacta Group SA Proposes Distribution | CI |
Mar. 13 | Medacta Group SA Provides Earnings Guidance for the Year 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.48 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.28 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.03% | 2.66B | B | ||
+2.93% | 197B | C+ | ||
+5.71% | 115B | C | ||
+1.36% | 71.22B | A | ||
+12.43% | 53.77B | B- | ||
+17.52% | 48.75B | B- | ||
+6.87% | 44.22B | B+ | ||
+12.60% | 28.85B | A- | ||
+10.14% | 28.57B | B | ||
+10.35% | 27.62B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Medacta Group SA - Swiss Exchange
- Ratings Medacta Group SA